High expression of Aldolase A predicts poor survival in patients with clear-cell renal cell carcinoma
Authors Na N, Li H, Xu CF, Miao B, Hong LQ, Huang ZY, Jiang Q
Received 26 September 2016
Accepted for publication 21 November 2016
Published 27 February 2017 Volume 2017:13 Pages 279—285
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Lucy Goodman
Peer reviewer comments 2
Editor who approved publication: Professor Deyun Wang
Ning Na,1,* Heng Li,1,* Chengfang Xu,2,* Bin Miao,1 Liangqing Hong,1 Zhengyu Huang,1 Qiu Jiang3
1Department of Kidney Transplantation, 2Department of Obstetrics and Genecology, The Third Affiliated Hospital of Sun Yat-sen University, 3Department of Organ Transplantation, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, People’s Republic of China
*These authors contributed equally to this work
Background: Aldolase A (ALDOA) is a glycolytic enzyme that drives the glycolytic metabolic pathway in mammalian cells. The overexpression of ALDOA was observed in a variety of cancers including clear-cell renal cell carcinoma (ccRCC). However, little was known about the clinicopathological significance and prognostic value of ALDOA in ccRCC patients.
Methods: The expression of ALDOA was detected using immunohistochemical staining in 162 formalin-fixed, paraffin-embedded ccRCC sections. Prognostic outcomes correlated with ALDOA were examined using Kaplan–Meier analysis and the Cox proportional hazards model.
Results: In patients with ccRCC, increased cytoplasmic ALDOA expression was positively associated with tumor size (P=0.021), TNM stages (P=0.034), lymph node metastasis (P=0.020), and overall survival (OS) (P<0.001). Kaplan–Meier analysis showed that high cytoplasmic expression of ALDOA was associated with a statistically significant lower OS (P<0.001). Multivariate analysis demonstrated that ALDOA expression was an independent and significant prognostic factor (HR =3.561, 95% CI =1.715–7.396, P=0.001). ALDOA expression was not associated with significant prognostic deference in the subgroups of TNM stage I patients or pT1 patients.
Conclusion: Our results suggest that ALDOA expression is an independent prognostic factor for OS in patients with ccRCC.
Keywords: renal carcinoma, Aldolase A, glycolysis, prognosis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]